Ranbaxy Labortites

ASSIGNMENT ON RANBAXY LABORATORIES Ltd.

Prepared By: ARUN SINGH MBA/4530/06

TOP 10 PHARMACEUTICALS IN INDIA  RANBAXY  Dr. REDDY‘s  CIPLA  NICHOLAS PIRAMAL AUROBINDO PHARMA GLAXO SMITH KLINE  LUPIN  SUN PHRMACEUTICALS CADILLA HEALTHCARE WOCKHARDT

RANBAXY LABORTITES Type Founded Headquarters Key People

: : : :

Industry

Public 1961 Gurgaon, Haryana, India Tejandra Khanna, Chairman Brian Tempest, Vice Chairman Malvinder Singh, CEO : Pharmaceutical

Total revenue Global revenue Market cap

: Rs. 5,188 crore : Rs. 3,819 crore : Rs. 15,077 crore

Number of countries where it is present Countries where it has manufacturing units

:

49

:

8

Revenue targeted by December 2007 Revenue targeted by December 2012

:

Rs. 9,400 crore ($ 2 billion)

:

Rs. 23,520 crore ($ 5 billion)

Employees

:

1100 in R&D

Website

:

www.ranbaxy.com

BOARD OF DIRECTORS Mr. Tejandra Khanna, Brian.W. Tempest, Mr. Malvinder Mohan Singh, Mr. Atul Sobti, Dr. P.S Joshi Ramesh L. Adige

Chairman Vice Chairman CEO & MD President Director Executive Director

VISION The company’s vision is to achieve significant business in proprietary products by 2012 with a strong presence in developed markets. It also aspires to be amongst the Top 5 generic players with US $ 5 billion in sales, by 2012.

CORE VALUES The core values in action that each manager of ranbaxy should subscribe are:  Performance Focus  Customer Responsiveness  Entrepreneurial Drive  Trustworthiness  People Development

PRODUCTS OFFERED  ANTI – INFECTION  G.I & NUTRITIONALS  CVS & DIABETES  CNS  NS AID & RELATED  ANTI ALLERGANTS  ANTI RETROVIRALS  UROLOGY  OTHERS

RANBAXY TOP 10 GENERICS 388.22

Co-amoxiclav

306.44

Amoxicillin

204.45

Ciprofloxacin

196.93

Cephalexm

Co-amoxiclav Amoxicillin Ciprofloxacin

189.88

Simvastatin

Cephalexm Simvastatin

172.96

Isotretinoin

Isotretinoin Cefaclos Clanthromycin

Cefaclos

118.91

Cefpoxoxime Ketrolac

Clanthromycin

Cefpoxoxime

Ketrolac

117.5 107.63 103.87

STRATEGIES  The Globalization Strategy  Growth Strategy  Poised For Growth  API Development And Production  Dosage Form Development And Manufacturing  Contract Manufacturing

COMPETITOR ANALYSIS

AT HOME Ranbaxy Vs The Top Five Domestic Companies 20000 18000 16000 14000 12000

Turnover PBT PAT Market cap

10000 8000 6000 4000 2000 0 Ranbaxy

GSK

Reddy's

Cipla

Nicholas

MARKET SHARE Ranbaxy 11%

GSK 1% Cipla 13%

Nicholas 7%

Others 60% Cadilla 8%

SURVEY ANALYSIS GSK 20% Ranbaxy 35%

Dr. Reddy's 18%

Cipla 27%

THANK YOU